Study BT8009-100 in Subjects With Nectin-4 Expressing Advanced Malignancies
A phase 1/2 trial of Zelenectide pevedotin and Pembrolizumab in bladder & urothelial cancer, triple-negative breast cancer, HR-positive / HER2-negative breast cancer, HER2-positive breast cancer, non-small-cell lung cancer and ovarian cancer, run by BicycleTx Limited, active and no longer recruiting.
Overview
Study BT8009-100 in Subjects With Nectin-4 Expressing Advanced Malignancies is a phase 1/2 interventional study registered as NCT04561362 by BicycleTx Limited, with 329 participants enrolled, started 2020-07-17 and due to reach its primary completion in 2026-03. Interventions recorded: BT8009 and Pembrolizumab.
Similar pages
not linked directly; found by shared links- TrialStudy to Assess GTAEXS617 in Participants With Advanced Solid Tumors
Shares Triple-negative breast cancer (TNBC), Ovarian cancer, HR-positive / HER2-negative breast cancer, Non-small-cell lung cancer and the tag pipeline.
- TrialStudy BT8009-230 in Participants With Locally Advanced or Metastatic Urothelial Cancer (Duravelo-2)
Shares Zelenectide pevedotin, Bladder & urothelial cancer, Pembrolizumab and the tag pipeline.
- TrialStudy of Zelenectide Pevedotin in Participants With Advanced Breast Cancer
Shares Zelenectide pevedotin and the tag pipeline.
- TrialA Phase I/II Study of VLS-1488 in Subjects With Advanced Cancer
Shares Triple-negative breast cancer (TNBC), Ovarian cancer, Non-small-cell lung cancer and the tag pipeline.
- TreatmentJK08
Shares Bladder & urothelial cancer, Triple-negative breast cancer (TNBC), Ovarian cancer, HR-positive / HER2-negative breast cancer and the tag pipeline.
- TrialDual-Target CAR-NK Cells for Advanced Breast Cancer HER2+ TNBC
Shares HER2-positive breast cancer, Triple-negative breast cancer (TNBC) and the tag pipeline.
- TrialModi-1 Moditope in Breast, Head and Neck, Ovarian, or Renal Cancer
Shares Triple-negative breast cancer (TNBC), Ovarian cancer, Pembrolizumab and the tag pipeline.
- TrialEfficacy and Safety of Pembrolizumab (MK-3475) in Combination With Bacillus Calmette-Guerin (BCG) in High-Risk Non-Muscle Invasive Bladder Cancer (HR NMIBC) (MK-3475-676/KEYNOTE-676)
Shares Bladder & urothelial cancer, Pembrolizumab and the tag pipeline.